Exclusive Enteral Nutrition versus Infliximab in Inducing Therapy of Pediatric Crohn’s Disease

Abstract EN

Aim.

To compare the effectiveness of exclusive enteral nutrition (EEN) and infliximab (IFX) therapy in pediatric Crohn’s disease (CD).

Methods.

In a prospective study of children initiating EEN or infliximab therapy for CD, we compared clinical outcomes using the pediatric Crohn’s disease activity index (PCDAI), growth improvement, endoscopic mucosal healing, and adverse effects.

Data were measured at baseline and after 8 weeks of therapy.

Results.

We enrolled 26 children with CD; of whom, 13 were treated with infliximab, 13 with EEN.

Clinical response (PCDAI) reduction ≥ 15 or final PCDAI ≤ 10 was achieved by 83.3% in the EEN group and 90.9% in the IFX group.

Body mass index for age (BMIFA) z-scores were significantly increased in both groups (P<0.05).

No significant differences were observed in PCDAI, height for age (HFA), or BMI recovery between two groups.

Adverse effects were detected in 30.7% on infliximab and 0% on EEN.

Mucosal healing was achieved in 71.4% cases in the EEN group versus 85.7% in the IFX group.

Conclusion.

EEN provided similar improvements as IFX in clinical symptoms, mucosal healing, and BMI.

EEN therapy has less adverse effects when compared with IFX.

This trial is registered with the Clinical Registration Number: ChiCTR-OON-17010834.